Stepan Company
NYSE:SCLChemicals - Specialty
+$0.46 today
- Market cap
- $1.50B
- Beta
- 0.97
- P/E (TTM)
- -87.3
- EPS (TTM)
- -$0.62
- Dividend yield
- 2.89%
Volume 0.13M
Average 0.15M
SCL EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Stepan CompanyNYSE: SCL
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns negative
Q1 FY2026 EBITDA was -$16.48M, compared with $57.81M a year earlier. Trailing-twelve-month EBITDA was $139.93M. Over 3 fiscal years it compounded at -10.3% a year.
Context
- EBITDA amounted to 9.1% of revenue in FY2025, up 0.3 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of $240.49M (+13.3%) for the fiscal year ending Dec 2026, a step up from the +10.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$16.48M-132.4% QoQ
- Last fiscal yearDec 2025
- $212.17M+10.4% YoY
- LTMMar 2026
- $139.93M-27.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -128.5% | +9.1% | +137.6 pp |
| 1 year | +10.4% | +13.3% | +2.9 pp |
| 3-year CAGR | -10.3% | +13.7% | +24.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 212.17M USD
- Year-over-year change
- +10.4%
- 4-year CAGR
- -5.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 212.17M | +10.4% |
| FY2024 | 2024-12-31 | 192.1M | +13.2% |
| FY2023 | 2023-12-31 | 169.68M | -42.3% |
| FY2022 | 2022-12-31 | 294.24M | +8.8% |
| FY2021 | 2021-12-31 | 270.42M | — |
EBITDA vs competitors
How SCL compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -27.5% is the 10th highest of 11, against a peer median of +14.6%.
- EBITDA amounts to 6.0% of revenue for SCL, versus a peer median of 18.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | R$6.93B BRL | +2564.8% | -57.3% | 10.4% | |
| LTM Mar 2026 | $252.23M USD | -2.0% | +4.9% | 13.4% | |
| LTM Mar 2026 | $235.69M USD | +22.6% | -19.4% | 36.6% | |
| LTM Mar 2026 | $151.69M USD | +37.7% | -13.1% | 18.5% | |
| LTM Mar 2026 | $143.17M USD | +374.2% | +5.5% | 7.4% | |
| LTM Mar 2026 | $139.93M USD | -27.5% | -10.3% | 6.0% | |
| LTM Apr 2026 | $118.71M USD | +6.6% | +14.2% | 18.1% | |
| LTM Apr 2026 | $88.81M USD | +1.7% | +64.4% | 18.1% | |
| LTM Mar 2026 | $79M USD | +248.7% | — | 33.5% | |
| LTM Mar 2026 | -$58.28M USD | -19.7% | — | 4.2% | |
| LTM Mar 2026 | -$170.61M USD | -417.3% | — | 633.6% | |
| Peer median (excluding SCL) | — | +14.6% | +4.9% | 18.1% | |
Competitors are the stored peer set for SCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.35B | 2.77B | 2.33B | 2.18B | 2.33B |
| Cost of Revenue | 1.95B | 2.35B | 2.05B | 1.91B | 2.06B |
| Gross Profit | 395.81M | 427.07M | 277.6M | 272.21M | 269.89M |
| Gross Margin | 16.9% | 15.4% | 11.9% | 12.5% | 11.6% |
| Research & Development | 62.69M | 66.63M | 59.04M | 55.67M | 59.28M |
| Selling, General & Admin | 152.09M | 161.21M | 141.57M | 143.91M | 139.56M |
| Operating Expenses | 225.03M | 219.73M | 218.99M | 201.73M | 200.51M |
| Depreciation & Amortization | 90.88M | 94.65M | 105.34M | 112.2M | 126.04M |
| EBITDA | 270.42M | 294.24M | 169.68M | 192.1M | 212.17M |
| EBITDA Margin | 11.5% | 10.6% | 7.3% | 8.8% | 9.1% |
| Operating Income | 170.78M | 207.34M | 58.61M | 70.48M | 69.38M |
| Operating Margin | 7.3% | 7.5% | 2.5% | 3.2% | 3.0% |
| Interest Income | 1.26M | 1.08M | 3.84M | 5.28M | 4.11M |
| Interest Expense | 7.01M | 10.89M | 15.95M | 19.47M | 26.23M |
| Other Income / Expenses | 1.76M | (18.63M) | (10.22M) | (10.04M) | (9.48M) |
| Income Before Tax | 172.54M | 188.7M | 48.39M | 60.44M | 59.9M |
| Pre-Tax Margin | 7.4% | 6.8% | 2.1% | 2.8% | 2.6% |
| Income Tax Expense | 34.64M | 41.55M | 8.19M | 10.07M | 13.01M |
| Net Income | 137.8M | 147.15M | 40.2M | 50.37M | 46.9M |
| Net Margin | 5.9% | 5.3% | 1.7% | 2.3% | 2.0% |
| EPS (Basic) | 6.01 | 6.46 | 1.77 | 2.21 | 2.05 |
| EPS (Diluted) | 5.92 | 6.38 | 1.75 | 2.20 | 2.05 |
| Weighted Avg Shares | 22.92M | 22.78M | 22.78M | 22.9M | 22.87M |
| Weighted Avg Shares (Diluted) | 23.29M | 23.06M | 22.95M | 22.93M | 22.89M |
Stepan Company
NYSE:SCL
Intrinsic Alpha fair value
Locked
Current Price
$66.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.